Lead Therapeutic Candidate: TTX-MC138
Small, non-coding strands of RNA have been identified as a significant player in the pathology of cancer. One of the first miRNAs shown to have aberrant expression in cancer was miR-10b. Since the inaugural study on miR-10b, its role in cancer has been extensively validated, as a master regulator of tumor cell viability and metastasis in a range of cancers, including breast, pancreatic, ovarian, colon, glioblastomas, and others. Clinical evidence demonstrated in >700 peer-reviewed publications over the last ten years supports the link between miR-10b and metastasis across at least 19 cancer indications.
TransCode’s lead therapeutic candidate, TTX-MC138, is designed to inhibit microRNA-10b (miR-10b) and eliminate metastasis. We believe that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others.
TransCode’s lead therapeutic candidate, TTX-MC138, is designed to inhibit microRNA-10b (miR-10b) and eliminate metastasis. We believe that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others.
|
|
Pre-Clinical Evidence
Metastatic Breast Cancer
In multiple pre-clinical models of triple-negative breast cancer (TNBC), treatment with low-dose chemotherapy and TTX-MC138 eliminated pre-existing local metastases in 100% of treated animals representative of stage II/III metastatic cancer. In models representative of stage IV metastatic cancer, treatment with low-dose chemotherapy and TTX-MC138 resulted in elimination of distant metastases in 65% of animals treated.
|
Notably, no recurrence of metastases occurred following TTX-MC138 treatment cessation.
|
|
|
Sources: Yoo B, et al. Cancer Res. 2015;75(20):4407-4415; Yoo B, et al. Sci Rep. 2017;7:45060; Figure 11 in S-1 Preclinical results of TTX-MC138 in models of metastatic breast cancer.
Pancreatic Cancer
Positive preclinical results achieved with its lead candidate therapeutic, TTX-MC138, in pancreatic adenocarcinoma.
TTX-MC138, applied as monotherapy, in a murine model of pancreatic adenocarcinoma, showed that forty percent (40%) of animals treated had complete responses, defined as complete regression of disease and long-term survival without recurrence.
TTX-MC138, applied as monotherapy, in a murine model of pancreatic adenocarcinoma, showed that forty percent (40%) of animals treated had complete responses, defined as complete regression of disease and long-term survival without recurrence.
|
Survival
|
miR-10b Inhibiton
|
Clinical Path Forward
A first in human Phase O study with TTX-MC138 is planned for 1H of 2023, and is expected to be followed by Phase I/II.
More About TTX-MC138
For additional information about our groundbreaking lead investigational candidate, TTX-MC138, see the information sheet below.
|
Other Candidates
Learn more about TransCode's other therapeutic candidates.